Related Experiment Video

Updated: Aug 12, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

B‑cell activating factor gene polymorphisms rs9514828 and rs1041569 increase preeclampsia risk

Kosar Shirvani Baghbabouie1, Danial Jahantigh1, Forough Forghani2

  • 1Department of Biology, Faculty of Science, University of Sistan and Baluchestan, Zahedan, Iran.

Personalized Medicine
|August 11, 2026
PubMed

Insights

Specific BAFF gene variations are linked to a higher risk of preeclampsia (PE) in Iranian women. These findings suggest BAFF polymorphisms could be useful biomarkers for assessing PE risk.

Area of Science:

  • Genetics
  • Obstetrics
  • Immunology

Background:

  • Preeclampsia (PE) is a significant pregnancy complication.
  • Genetic factors are implicated in PE susceptibility.
  • BAFF gene polymorphisms are potential candidates for investigation.

Purpose of the Study:

  • To investigate the association between BAFF gene polymorphisms (rs1041569 and rs9514828) and preeclampsia susceptibility in an Iranian population.
  • To explore the relationship between these polymorphisms and PE severity and onset timing.

Main Methods:

  • A case-control study involving 560 pregnant women (280 PE, 280 controls) from Zahedan, Iran.
  • Genotyping using PCR-RFLP.
  • Statistical analysis with logistic regression to determine odds ratios (ORs) and 95% confidence intervals (CIs).

Main Results:

  • The CT and TT genotypes of rs9514828 were associated with increased PE risk (OR=1.81, p=0.011; OR=2.13, p=0.002).
  • The AT and TT genotypes of rs1041569 also showed increased PE risk (OR=1.48, p=0.033; OR=1.68, p=0.037).
  • Haplotype analysis indicated protective effects for C-A and T-T haplotypes (OR=0.69, p=0.003 for both).

Conclusions:

  • BAFF gene polymorphisms are significantly associated with preeclampsia susceptibility in the Iranian population.
  • These polymorphisms may serve as potential biomarkers for preeclampsia risk assessment.
Abstract

Keywords:
BAFFPCR-RFLPPreeclampsiapolymorphismrs1041569rs9514828

More Related Videos

Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas05:31

Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas

Published on: January 26, 2024

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)

Published on: August 21, 2016

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Comparing Copy Number Variations and SNPs02:26

Comparing Copy Number Variations and SNPs

Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...